- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00006203
Naltrexone, Craving, and Drinking
June 11, 2025 updated by: Peter Monti, Brown University
Naltrexone, Craving, and Drinking: Ecological Assessment
This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions.
Participants will monitor and record their daily desires to drink, environmental circumstances in which urges occur, and drinking behavior using a palm top computer.
Participants will receive naltrexone or a placebo.
One week after receiving medication, all participants will be asked to respond to alcohol-related cues that may or may not arouse the desire to drink.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
180
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02919
- Center for Alcohol and Addiction Studies, Brown University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Drink at least 4 days per week with 2 heavy drinking days (more than 6 standard drinks for men, more than 5 drinks for women) per week on average during the month prior to the study.
Exclusion Criteria:
- Current interest in treatment or a history of treatment for alcohol problems.
- History of liver disease or current liver function tests greater than five times normal.
- Opiate abuse or dependence, any opiate use two weeks before the study or a urine test screen that is positive for opiates.
- Females, who are pregnant, nursing, or not using reliable birth control method.
- Daily use of acetaminophen.
- Living with someone who participated in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Naltrexone Arm
Three weeks of daily 50mg Naltrexone
|
Daily 50 mg for 3 weeks
|
|
Placebo Comparator: Placebo Arm
Three weeks of daily placebo (sugar)
|
Daily doses of placebo for 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion
May 1, 2005
Study Registration Dates
First Submitted
September 11, 2000
First Submitted That Met QC Criteria
September 11, 2000
First Posted (Estimated)
September 12, 2000
Study Record Updates
Last Update Posted (Actual)
June 13, 2025
Last Update Submitted That Met QC Criteria
June 11, 2025
Last Verified
October 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIAAAMON0785011A1
- R01AA007850 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholism
-
Yale UniversityCompletedFamilial Alcoholism VulnerabilityUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingFamilial Alcoholism VulnerabilityUnited States
-
Yonsei UniversityTerminated
-
University of Southern DenmarkActive, not recruitingGeneral Practice | Alcohol Abuse Alcoholism | Screening and Brief InterventionDenmark
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedEffects of Family History of Alcoholism and Sex on Alcohol AnalgesiaUnited States
-
Versailles HospitalNot yet recruiting
-
Khoo Teck Puat HospitalNot yet recruitingEmergencies | Alcohol Use Disorder | Alcoholism and Alcohol Abuse
-
Brown UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcoholic Liver Disease | Alcoholism,United States
-
Johns Hopkins UniversityNational Institutes of Health (NIH); Idorsia Pharmaceuticals Ltd.Not yet recruitingAlcohol Use Disorder
-
Zealand University HospitalNot yet recruiting
Clinical Trials on Naltrexone 50 Mg
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Research Foundation for Mental Hygiene...Completed
-
State University of New York - Upstate Medical...CompletedAutism Spectrum DisorderUnited States
-
Alkermes, Inc.Completed
-
Abivax S.A.Quotient SciencesRecruiting
-
Zydus Lifesciences LimitedCompletedAmyotrophic Lateral SclerosisIndia
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol DependenceUnited States
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedProlonged Grief DisorderUnited States